An knowledgeable committee of the Central Drugs Standard Control Organisation (CDSCO) will meet on Wednesday to evaluation functions of Pfizer, Serum Institute of India and Bharat Biotech looking for emergency use authorisation for his or her Covid-19 vaccine candidates, official sources mentioned on Monday evening.
The determination was taken late on Monday night after the Hyderabad-based Bharat Biotech turned the third pharmaceutical agency to use to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed Covid-19 vaccine Covaxin.
The Indian arm of US pharmaceutical big Pfizer had on December four sought approval for its vaccine from the central drug regulator, after the agency secured such clearance within the UK and Bahrain.
The Pune-based Serum Institute of India sought the nod for the Oxford Covid-19 vaccine, Covishield, on December 6.
“DCGI has already started processing the applications. The subject expert committee (SEC) on Covid-19 at CDSCO will deliberate on the applications by Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorisation for their COVID-19 vaccines on December 9,” a supply mentioned.
After analysis, the SEC will give its suggestions to the DCGI on whether or not emergency use approval for the vaccine candidates ought to be granted or not, the supply mentioned.
At an all-party assembly on December four, Prime Minister Narendra Modi had expressed hope Covid-19 vaccine could also be prepared in a number of weeks.